Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients

Lupus Science and Medicine

Volumn 1, Issue 1, 2014, Pages

  Draborg, Anette Holck ^a   Jacobsen, Søren ^b   Westergaard, Marie ^a   Mortensen, Shila ^a   Larsen, Janni Lisander ^b   Houen, Gunnar ^a   Duus, Karen ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD69 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS EARLY ANTIGEN DIFFUSE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS INFECTION; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INTERFERON PRODUCTION; LYMPHOCYTE COUNT; MALE; NONHUMAN; PRIORITY JOURNAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 84929365668     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2014-000015     Document Type: Article

References (52)

1. Pons-Estel GJ, Alarcon GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257-68.
2. Dall'era M, Chakravarty EF. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep 2011;13:308-16.
3. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39.
4. Smith PP, Gordon C. Systemic lupus erythematosus: clinical presentations. Autoimmun Rev 2010;10:43-5.
5. Namjou B, Kilpatrick J, Harley JB. Genetics of clinical expression in SLE. Autoimmunity 2007;40:602-12.
6. Gross AJ, Hochberg D, Rand WM, et al. EBV and systemic lupus erythematosus: A new perspective. J Immunol 2005;174:6599-607.
7. Kang I, Quan T, Nolasco H, et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 2004;172:1287-94.
8. Moon UY, Park SJ, Oh ST, et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 2004;6:R295-302.
9. Yu SF, Wu HC, Tsai WC, et al. Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Med Microbiol Immunol 2005;194:115-20.
10. Auwaerter PG. Infectious mononucleosis in middle age. JAMA 1999;281:454-9.
11. Tattevin P, Le TY, Minjolle S, et al. Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis: surveillance study. J Clin Microbiol 2006;44:1873-4.
12. Babcock GJ, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000;13:497-506.
13. Joseph AM, Babcock GJ, Thorley-Lawson DA. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 2000;74:9964-71.
14. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1:75-82.
15. Schepers A, Pich D, Hammerschmidt W. Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1. Virology 1996;220:367-76.
16. Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008;41:298-328.
17. Steven NM, Annels NE, Kumar A, et al. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virusinduced cytotoxic T cell response. J Exp Med 1997;185:1605-17.
18. Setsuda J, Teruya-Feldstein J, Harris NL, et al. Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol 1999;155:257-65.
19. Jones JF, Straus SE. Chronic Epstein-Barr virus infection. Annu Rev Med 1987;38:195-209.
20. Ooka T, de Turenne-Tessier M, Stolzenberg MC. Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases. Springer Semin Immunopathol 1991;13:233-47.
21. Schwarzmann F, Jager M, Hornef M, et al. Epstein-Barr viral gene expression in B-lymphocytes. Leuk Lymphoma 1998;30:123-9.
22. Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 2008;22:883-96.
23. James JA, Neas BR, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001;44:1122-6.
24. Larsen M, Sauce D, Deback C, et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog 2011;7:e1002328.
25. Berkun Y, Zandman-Goddard G, Barzilai O, et al. Infectious antibodies in systemic lupus erythematosus patients. Lupus 2009;18:1129-35.
26. Chen CJ, Lin KH, Lin SC, et al. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. J Rheumatol 2005;32:44-7.
27. Chen DY, Chen YM, Lan JL, et al. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: The Epstein-Barr virus connection? J Clin Virol 2010;49:290-5.
28. Draborg A, Jorgensen J, Muller H, et al. Epstein-Barr virus early antigen diffuse (EBV-EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients. Scand J Rheumatol 2012;41:280-9.
29. Esen BA, Yilmaz G, Uzun S, et al. Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: A controlled study. Rheumatol Int 2010;32:79-83.
30. Huggins ML, Todd I, Powell RJ. Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus. Rheumatol Int 2005;25:183-7.
31. James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-26.
32. Lu JJ, Chen DY, Hsieh CW, et al. Association of Epstein-Barr virus infection with systemic lupus erythematosus in Taiwan. Lupus 2007;16:168-75.
33. McClain MT, Poole BD, Bruner BF, et al. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum 2006;54:360-8.
34. Parks CG, Cooper GS, Hudson LL, et al. Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum 2005;52:1148-59.
35. Stratta P, Canavese C, Ciccone G, et al. Correlation between cytomegalovirus infection and Raynaud's phenomenon in lupus nephritis. Nephron 1999;82:145-54.
36. Zandman-Goddard G, Berkun Y, Barzilai O, et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann N Y Acad Sci 2009;1173:658-63.
37. Csuka D, Simon D, Hobor R, et al. Serum concentration of immunoglobulin G-type antibodies against the whole Epstein-Barr nuclear antigen 1 and its aa35-58 or aa398-404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis. Clin Exp Immunol 2013;171:255-62.
38. Tsokos GC, Magrath IT, Balow JE. Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol 1983;131:1797-801.
39. Berner BR, Tary-Lehmann M, Yonkers NL, et al. Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell Immunol 2005;235:29-38.
40. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
41. Levitskaya J, Sharipo A, Leonchiks A, et al. Inhibition of ubiquitin/ proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997;94:12616-21.
42. Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E, et al. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993;178:537-47.
43. Testi R, Phillips JH, Lanier LL. T cell activation via Leu-23 (CD69). J Immunol 1989;143:1123-8.
44. Blake N, Haigh T, Shaka'a G, et al. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. J Immunol 2000;165:7078-87.
45. Buseyne F, Le GS, Boccaccio C, et al. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat Med 2001;7:344-9.
46. Carbone FR, Bevan MJ. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990;171:377-87.
47. Kovacsovics-Bankowski M, Clark K, Benacerraf B, et al. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 1993;90:4942-6.
48. Ackerman AL, Cresswell P. Cellular mechanisms governing crosspresentation of exogenous antigens. Nat Immunol 2004;5:678-84.
49. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350-4.
50. Groux H, Cottrez F, Montpellier C, et al. Isolation and characterization of transformed human T-cell lines infected by Epstein-Barr virus. Blood 1997;89:4521-30.
51. Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001;98:1882-8.
52. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001;98:280-6.